IntelGenx enters amended, restated license agreement with Tetra Bio Pharma

IntelGenx (IGXT) announced that it has entered into an amended and restated license agreement granting Tetra Bio-Pharma (TBPMF) additional exclusive worldwide rights, including the right to manufacture, IntelGenx's Adversa mucoadhesive delivery technology. The Adversa technology is designed to limit first-pass metabolism, improve bioavailability, enhance product stability and reduce gastro-intestinal exposure and side-effects. Tetra will use the Adversa technology to develop a THC-based mucoadhesive film containing its PPP-002 drug candidate for the treatment of chemotherapy-induced nausea and vomiting. Under the terms of the Agreement, Tetra is purchasing the worldwide Adversa technology rights as it relates to its PPP-002 drug product candidate for three undisclosed milestone payments: 45% to be paid on November 15, 2020; 45% to be paid on March 1, 2021, and a final payment of 10% upon successful technology transfer. In addition, Tetra will pay IntelGenx a low single digit royalty on future net sales of Dronabinol mucoadhesive tablets.